🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million instances annually. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in close succession. This medication, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to data released by a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The research involved hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Clinicians on the front lines have expressed hope. Access to a single-dose, oral treatment like this is described as a "game-changer" for public health efforts. This is deemed crucial to lessen the impact of the infection for patients and to halt the transmission of extremely resistant gonorrhoea around the world.